November 2018
Welcome to the November issue. Upfront investigates the transparency of European clinical trials, gene-editing to protect mice from cocaine overdose and addiction, and how the FDA thinks manufacturing can be modernized. Frank Cordes explains how integrating automation and informatics will be made possible by Industry 4.0 in “In My View,” while our cover feature explores the pharma industry’s role in biodefense. In Best Practice, Mario Philips, Vice President and General Manager at Pall Biotech, discusses the evolution of single-use technology; and in Business, academics from the Campbell School of Business in the US explain the empirical evidence linking technology and financial decisions for start-ups in the pharma industry. We also Sit Down With Vivek Sharma, CEO of Piramal Pharma Solutions.
Back to Basics
November 16, 2018
David Walker, Executive Director of the Center for Biodefense and Emerging Infectious Diseases
0 min read
A Winning Bid
November 14, 2018
Founded in 1998, Emergent BioSolutions has gone on to become a multinational biopharma company – despite working in some difficult therapeutic areas, including biodefense.
0 min read
The Intersection of Infection and Biodefense
November 14, 2018
Marcus Horwitz’s primary focus is on infectious diseases, but a number of pathogens he has studied led him into the realm of bioterrorism. Recently, Horwitz and his team has developed a single vector vaccine platform that could offer protection against tularemia, anthrax, plague, and melioidosis – all considered significant bioterrorism threats.
0 min read
Rising to the Challenge
November 14, 2018
Biodefense is not just about offering protection from bioterror attacks; it’s also about being prepared for emerging infectious diseases.
0 min read
Easing Ion-Exchange Chromatography
November 14, 2018
Why salt-tolerant resins make for “happier” biomolecules with better binding.
0 min read
Changing Mindsets
November 14, 2018
Sitting Down With... Vivek Sharma, CEO of Piramal Pharma Solutions.
0 min read
The Winning Strategy for Start-Ups
November 14, 2018
Business academics have been trying to uncover empirical evidence around how financing decisions are linked with technology. After all, the business of making biopharmaceuticals is expensive – so the more data you have to back up decisions, the better.
0 min read
The New Antibody Formats on the Block
November 14, 2018
More complex alternatives to monoclonal antibodies are demanding innovation from manufacturing and purification techniques.
0 min read
The Next Chapter in Single Use
November 14, 2018
Disposable technology has found its place in the biopharma industry, but where does the story go from here?
0 min read
Keys to Consistent Bioprocessing
November 14, 2018
The development of a robust and consistent bioprocess requires a systematic and risk-based approach to identify the right process parameters and raw materials.
0 min read
Outbreak
November 14, 2018
Meet the companies and researchers protecting us from bioterrorists who plan to harness the destructive power of infectious diseases.
0 min read
All Eyes on E&Ls
November 14, 2018
Extractables and leachables require rigorous analysis to protect patient safety. Here, we speak with Saskia Haehn – an expert when it comes to diving deep into materials.Extractables and leachables require rigorous analysis to protect patient safety. Here, we speak with Saskia Haehn – an expert when it comes to diving deep into materials.
0 min read
The Revolution Rises
November 14, 2018
Pharma lags behind in the adoption of new technologies compared with other industries, but discussion around Industry 4.0 is increasing – and we are making progress.
0 min read
The Good and the Bad of Biosimilars
November 14, 2018
The biosimilars market is suddenly booming, with established biopharma giants and nimble start-ups all clamoring for a piece of the action. But such steep competition means that only the wise will survive.
0 min read
I’m a (Blockchain) Believer
November 14, 2018
The pharma industry is built on data; distributed ledger technology could transform how we use, share, interact with and benefit from it.
0 min read
Trials of a Medicine Maker
November 14, 2018
Outsourcing Buffer Management is Smart Thinking
0 min read
Business-in-Brief
November 14, 2018
A new gene therapy, a procurement process gone wrong, and backing away from a biosimilar… What’s new for pharma in business?
0 min read
Solutions In Silico
November 14, 2018
Collaboration seeks to use artificial intelligence to predict how patients will respond to immunotherapy
0 min read
Seeds of Change
November 14, 2018
A nanofluidic device, smaller than a grain of rice, aims to deliver localized immunotherapy without side effects
0 min read
Coke Zero’d
November 14, 2018
Genetically engineered skin cells expressing highly potent cocaine hydrolase reduce cocaine-seeking behavior in mice
0 min read
How Transparent Are Trials?
November 14, 2018
Only 50 percent of clinical trial results in Europe are reported, but big pharma shares far less than half the blame
0 min read
Press It! Plug It! Play It!
November 14, 2018
A new automated chemical synthesis machine aims to remove some of the repetitive processes from a scientist’s day
0 min read
Business & Regulation
Small Molecules
Facilities & Equipment
Technology & Manufacturing
Regulation & Standards
Business & Trends
Let’s Modernize Manufacturing
November 14, 2018
The FDA’s Janet Woodcock says that manufacturing will change in the coming years. How? The answer lies in the hands of industry
0 min read
The Face of Science (and the Fifty Pound Note)
November 14, 2018
Recognizing and celebrating the efforts of both male and female scientists
0 min read
